dc.contributor.author |
Lawal, Ismaheel Opeyemi
|
|
dc.contributor.author |
Abubakar, Sofiullah O.
|
|
dc.contributor.author |
Ndlovu, Honest
|
|
dc.contributor.author |
Mokoala, Kgomotso M.G.
|
|
dc.contributor.author |
More, Stuart
|
|
dc.contributor.author |
Sathekge, Mike Machaba
|
|
dc.date.accessioned |
2024-06-19T09:33:03Z |
|
dc.date.issued |
2024-05 |
|
dc.description.abstract |
Please read abstract in the article. |
en_US |
dc.description.department |
Nuclear Medicine |
en_US |
dc.description.embargo |
2025-03-31 |
|
dc.description.librarian |
hj2024 |
en_US |
dc.description.sdg |
SDG-03:Good heatlh and well-being |
en_US |
dc.description.uri |
https://link.springer.com/journal/40291 |
en_US |
dc.identifier.citation |
Lawal, I.O., Abubakar, S.O., Ndlovu, H. et al. Advances in Radioligand Theranostics in Oncology. Molecular Diagnosis & Therapy 28, 265–289 (2024). https://doi.org/10.1007/s40291-024-00702-4. |
en_US |
dc.identifier.issn |
1177-1062 (print) |
|
dc.identifier.issn |
1179-2000 (online) |
|
dc.identifier.other |
10.1007/s40291-024-00702-4 |
|
dc.identifier.uri |
http://hdl.handle.net/2263/96534 |
|
dc.language.iso |
en |
en_US |
dc.publisher |
Springer |
en_US |
dc.rights |
© The Author(s), under exclusive licence to Springer Nature Switzerland AG 2024. The original publication is available at : https://link.springer.com/journal/40291. |
en_US |
dc.subject |
Lutetium-177 DOTATATE (177Lu-DOTATATE) |
en_US |
dc.subject |
Lutetium-177 prostate-specific membrane antigen (177Lu-PSMA) |
en_US |
dc.subject |
Fibroblast activation protein (FAP) |
en_US |
dc.subject |
Chemokine receptor 4 (CXCR4) |
en_US |
dc.subject |
Radioligand |
en_US |
dc.subject |
Theranostics |
en_US |
dc.subject |
Oncology |
en_US |
dc.subject |
SDG-03: Good health and well-being |
en_US |
dc.title |
Advances in radioligand theranostics in oncology |
en_US |
dc.type |
Postprint Article |
en_US |